Sarepta Therapeutics Inc. (NASDAQ:SRPT) reported on Tuesday that the first-quarter 2025 loss of $3.42 per share was missing the analyst consensus estimate of losses of 95 cents.
Quarterly revenue came in at $744.86 million, beating the consensus estimate of $683.36 million.
According to Sarepta CEO Doug Ingram, the company also faced headwinds in the quarter.
“While we are taking a variety of actions to address and resolve these challenges, we have adjusted our guidance for 2025 to $2.3 billion to $2.6 billion,” Ingram said. “The broader biotech market has also faced significant pressure in the first quarter of 2025. Fortunately, as an organization with four life-changing therapies, significant revenue, and a deep pipeline, Sarepta is well-positioned to navigate these chaotic times.”
Also Read: Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death
Guidance: Sarepta revised its 2025 total net product revenues guidance to $2.3-$2.6 billion from $2.9-$3.1 billion.
William Blair writes that the revised guidance primarily relates to delayed Elevidys turnaround times.
The time from starting treatment paperwork to actual infusion takes about 1 to 1.5 months longer than expected. This delay is mostly due to stricter screening steps added to protect patients in the larger treatment group, analyst Sami Corwin says. Although the company is trying to speed things up and reduce delays, it expects these early-year trends to continue throughout the rest of the year.
“We view the miss in total net product and Elevidys revenue as unfortunate and disappointing given the macroeconomic overhangs that have already caused the stock to come under pressure,” William Blair writes.
The analyst adds that management believes the impact on Elevidys's revenue will be temporary, and expects demand to pick up in the second half of the year, starting in the summer.
Price Action: Sarepta Therapeutics stock is down 19.4% at $37.67 at last check Wednesday.
Read Next:
Image: Shutterstock
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.